Ceftaroline

ApprovedSmall molecule

Pfizer

Ceftaroline is one of 174 small molecule programs targeting Bacterial Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

173

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial DiseaseActive, not recruiting

Bacterial PneumoniaActive, not recruiting

ToxicityActive, not recruiting

Skin InfectionActive, not recruiting

PneumoniaActive, not recruiting

Cystic FibrosisActive, not recruiting

Bacterial DiseasePhase 3

Active, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

ToxicityApproved

Active, not recruiting

Skin InfectionPhase 3

Active, not recruiting

PneumoniaPhase 1

Active, not recruiting

Cystic FibrosisApproved

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Ceftaroline

Pfizer

Approved

2 2

Acanya

Pfizer

Preclinical

1 3

Prevacid

Takeda

Preclinical

1 4

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 5

Advil

KKenvue Brands

Preclinical

2 6

Ofev

Boehringer Ingelheim

Preclinical

1 7

Cancidas

FFresenius Kabi Oncology Ltd.

Preclinical

1 8

Pepcid

KKenvue Brands

Preclinical

1 9

Aciphex

Akero Therapeutics

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Pneumonia

NCT02735707

Clinical

Trials by Indication[1]

Pneumonia2 trials

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance

Completed·PPoitiers University Hospital·Phase 1·NCT03025841·18 enrolled

Tics2 trials

Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age

Completed·FForest Laboratories·Phase 1·NCT00633126·9 enrolled

Ceftaroline China Pharmacokinetics Study

Completed· Pfizer logo

Pfizer·Phase 1·NCT01458743·24 enrolled

Bacterial Pneumonia2 trials

A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

Completed· Pfizer logo

Pfizer·Phase 3·NCT01371838·848 enrolled

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

Completed·—·Phase 4·NCT01524302·12 enrolled

Skin Infection2 trials

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Completed·FForest Laboratories·Phase 3·NCT00424190·698 enrolled

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Completed·FForest Laboratories·Phase 3·NCT00423657·680 enrolled

Prophylaxis1 trial

The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection

Unknown status·UUniversity of Cincinnati·Phase 4·NCT02307006·500 enrolled

10 more indications

Obese1 trial

Pharmacokinetics of Ceftaroline in Normal and Obese Subjects

Completed·—·Phase 1·NCT01648127·32 enrolled

Antibiotic Prophylaxis1 trial

Antibiotic Prophylaxis in Open Fractures

Unknown status·—·Phase 4·NCT02937181·50 enrolled

Children1 trial

Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

Unknown status·BBasim Asmar·Phase 1·NCT02600793·12 enrolled

Bone and Joint Infection1 trial

Ceftaroline in the Treatment of Bone and Joint Infections

Withdrawn·OOrlando Health, Inc.·Phase 4·NCT02005068

Toxicity1 trial

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Terminated·HHenry Ford Health System·Phase 4·NCT01734694·100 enrolled

Antibiotic1 trial

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

Completed·SSharp HealthCare·Phase 4·NCT02660346·40 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Completed·FForest Laboratories·Phase 2·NCT00633152·150 enrolled

Double-blind1 trial

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT01290900·54 enrolled

Outcome1 trial

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Completed·WWayne State University·Phase 4·NCT02582203·174 enrolled

Cystic Fibrosis1 trial

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

Completed·—·Phase 4·NCT03771313·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Ceftaroline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftaroline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftaroline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Ceftaroline

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Pneumonia2 trials

Tics2 trials

Bacterial Pneumonia2 trials

Skin Infection2 trials

Prophylaxis1 trial

Obese1 trial

Antibiotic Prophylaxis1 trial

Children1 trial

Bone and Joint Infection1 trial

Toxicity1 trial

Antibiotic1 trial

Efficacy and Safety1 trial

Double-blind1 trial

Outcome1 trial

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News